Background: Elderly patients with advanced non-small-cell lung cancer (NSCLC) with poor performance status (PS) are a special population requiring particular attention. Single-agent oral vinorelbine could be an attractive option.
introduction
Non-small-cell lung cancer (NSCLC) represents 80% of all lung cancers. At the time of diagnosis, the majority of patients have metastatic disease and a systemic palliative treatment is the only therapeutic option. More than 50% of cases of advanced NSCLC are diagnosed in patients >65 years of age, and 30%-40% of cases are diagnosed in patients >70 years of age [1] . Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of two or more usually account for a small proportion of patients enrolled in trials of first-line treatment of advanced disease [2] [3] [4] but represent a significantly higher proportion (up to 30%-40%) when population-based surveys are conducted [5] . The benefit achievable with cisplatin-based chemotherapy seems more evident for fit patients (PS ‡0 or 1) and there is no consistent evidence about the real efficacy of platinum-based treatment of patients with a PS of two or more [6] . The elderly patients with PS ‡2 constitute a special population in which the 'standard' of care continues to evolve and data from randomized trials are largely confined to subgroup analysis. If chemotherapy is appropriate for some patients with PS of two or more, which agents are appropriate is not clear. Evidences from subgroup analysis showed that PS ‡2 patients should be treated with monochemotherapy or less toxic doublets. Elderly patients with advanced NSCLC often present with medical comorbidities and social problems that make the selection of the optimal treatment quite challenging [7] . So, validated instruments to evaluate functional status, comorbidities, socioeconomic issues, nutritional status, polypharmacy and the presence of geriatric syndromes, such as a comprehensive geriatric assessment (CGA), are mandatory to add substantial information with respect to the functional assessment of elderly cancer patients, allowing important prognostic discrimination [8] . The need to warrant an effective treatment for this special population with particular attention to safety aspects led us to explore the role of oral vinorelbine as single-agent chemotherapy.
patients and methods eligibility criteria supraclavicular lymph nodes) or metastatic (stage IV) NSCLC aged ‡70 years with measurable disease (according to RECIST criteria) [9] were eligible for the study. All patients underwent pretreatment evaluation by means of Basic Activities of Daily Living (BADL) [10] and Instrumental Activities of Daily Living (IADL) [11] questionnaires. All patients must obtain a score >5 for BADL and >7 for IADL to have a good functional status and for being consequently suitable for study entry. Patients presenting with three or more geriatric syndromes were excluded. Additional entry criteria included ECOG PS of two or more, a life expectancy of at least 3 months, adequate bone marrow reserve and adequate hepatic and renal function. Patients with previous or concomitant malignancies (excluding nonmelanoma skin cancer and in situ cervical cancer treated with radical surgery) or any uncontrolled comorbidity potentially interfering with treatment were excluded. We excluded patients with symptomatic brain metastases. Previous radiotherapy, completed at least 4 weeks before study entry, on nontarget lesions was allowed. Concomitant radiotherapy was not allowed. A previous chemotherapy regimen was permitted. Written informed consent was obtained before study entry and study procedures were in accordance with Helsinki Declaration.
Baseline evaluation included complete medical history, physical examination, symptom assessment, PS determination, complete blood cell count and serum chemistry. Baseline staging consisted of chest X-ray coupled with abdominal ultrasound or computed tomography (CT) scan of the thorax and upper abdomen. Brain CT and bone scan were reserved for symptomatic patients. Health-related quality of life (HRQoL) was assessed at baseline, every two cycles and at study end by means of the Italian version of Functional Assessment of Cancer Therapy-Lung version 4 (FACT-L v4) questionnaire. Briefly, FACT-L v4 questionnaire is made up of five domains investigating all aspects of patient life (physical, social/familiar, emotional, functional wellness and symptom perception). Each domain is composed of various multiple-choice queries with increasing answer scores.
study design and treatment
Oral vinorelbine was administered at the dose of 60 mg/m 2 on days 1-8 every 3 weeks. Vinorelbine soft gelatin capsules were taken after a meal without chewing or sucking the capsules. Individual doses were rounded to the closest multiple of 10 mg by using a combination of 20-and 30-mg capsules. No primary prophylaxis with antiemetics was recommended. In case of nausea/vomiting, we recommended alizapride. If nausea/vomiting still occurred, a 5-HT3 antagonist plus dexamethasone were recommended. In case of diarrhea, loperamide was recommended. Granulocyte colonystimulating factors were allowed in patients reporting grade 3 neutropenia with fever lasting three days or more or in case of grade 4 neutropenia. The use of erythropoietin was allowed according to European Organisation for Research and Treatment of Cancer guidelines [12] . Treatment plan consisted of a maximum of nine cycles with early stop in case of disease progression, patient refusal or excessive toxicity. Dose increase to 80 mg/m 2 with the same schedule was permitted in patients experiencing clinical benefit (CB) after the first two cycles without toxicity more than grade 2.
Patients were seen at every dose administration during treatment and complete blood cell count and serum chemistry were carried out. Dose adjustment made was as follows: if grade 3/4 hematologic or nonhematologic toxicity occurred at any time during the cycle, dose was reduced of 25% at first occurrence and of 50% at second occurrence. If grade 3/4 toxicity still occurred, treatment was permanently stopped. If grade 3/4 toxicity was present at the time of drug administration, the dose was delayed until toxicity reduced to <grade 3 and administered according to dose reduction plan. If grade 3/4 toxicity was present at day 8, dose was omitted. Patients received any palliative treatment (other than chemotherapy) according to physician judgment.
disease assessment and study objectives
Disease evaluation was carried out by thorax CT scan or chest X-ray coupled with abdominal ultrasound (according to baseline method) every two cycles during treatment. During follow-up, disease evaluation was carried out every 2 months for the first 6 months and every 3 months thereafter. Primary end points were response rate (RR) (according to RECIST criteria) and safety. Secondary end points were time to progression (TTP), overall survival (OS), the percentage of alive patients at 1 year and HRQoL. Complete response (CR) was defined as the disappearance of all lesions without the appearance of new lesions. A partial response (PR) required at least 30% tumor reduction lasting for at least four weeks (less than a 30% reduction and less than a 20% increase in the sum of the products of two perpendicular diameters of all measured lesions and the appearance of no new lesions). TTP was calculated from the date of treatment start to the date of first-documented progression. OS was defined as the time interval between the start of study treatment and death or last follow-up contact. Adverse events were recorded according to the Common Terminology Criteria for Adverse Events version 3.1 (CTCAE v3.1).
statistical methods
Given a low-interest RR (P 0 ) of 10% and a treatment-related RR of clinical interest (P 1 ) of 25%, an a error of 0.05 and b error of 0.2, according to Simon's Minimax design for two-step phase II trial, we will aim to enroll 18 patients at first step. In case of treatment responses more than two, the enrollment will continue to a total of 43 patients. Study treatment will be considered of clinical interest in case of a total treatment responses of more than seven. All data were analyzed at a cut-off date in June 2009. TTP was defined as the time interval between treatment start and disease progression or patient death related to disease progression. OS was defined as the time interval between treatment start and patient death. Survival parameters (TTP and OS) were expressed as median and range. In the subgroup analysis, they were expressed as median and 95% confidence interval and their differences were tested for significance with Student's t-test. Table 1 . Median age was 77 (range 70-89) years. The wide majority of study population was composed of males (36 of 43) with squamous cell histology tumors (24 of 43). In 54% of patients (23 of 43), oral vinorelbine was administered as first-line treatment and ECOG patients with a PS of two or more represented 83% (36 of 43) of the whole population (Table 1) .
drug administration
A total of 187 cycles corresponding to 374 administrations of oral vinorelbine were given with a median number of cycles of 4 (range 2-9). All patients received at least two cycles with 58.1% (25 of 43) that received at least four cycles. One-step dose reduction of 25% occurred in only one patient due to notfebrile grade 3 neutropenia observed at day 14 of the first cycle. After dose reduction, the patient did not experience any further significant toxicity. Dose escalation to 80 mg/m 2 was done in Figure 1 . Aimed to identify responder patients, we carried out an unplanned subgroup analysis taking into consideration sex, PS (2 versus 3), age (<77 versus ‡77 years), histotype (squamous versus nonsquamous) and previous chemotherapy (yes versus no). RR and CB did not differ between the two groups. Survival subgroup analysis demonstrated a TTP advantage only for older patients (<77 versus ‡77 years; 3.5 [2] [3] [4] [5] Table 3 ).
toxicity and QoL
Study treatment was extremely safe. With the exception of one single not-febrile grade 3 neutropenia episode spontaneously recovered, all the observed toxic effects were mild (grade 1/2). Regardless of grade, most common non-hematological toxic effects were fatigue (32.6%), nausea (48.1%), vomiting (22.9%), mucositis (18.5%) and diarrhea (25.4%) ( Table 4) . Grade 1/2 hematological toxic effects observed were neutropenia (16.4%), leukopenia (23.2%) and anemia (43.2%) ( Table 4 ). There was no treatment-related death and none of the study patients required hospitalization for treatmentrelated adverse events. Moreover, during treatment, no patient required blood or platelet transfusions or i.v. antibiotics and granulocyte colony-stimulating factors were not used. Only the patient that experienced grade 3 not-febrile neutropenia received oral antibiotic prophylaxis for a week from day 14-20 of first cycle.
Given the very special study population, HRQoL assessment is of primary importance and it has been carefully assessed during treatment. Comparing mean baseline FACT-L v4 scores with those obtained during treatment and at end-study time, we did not observe any significant difference in the five questionnaire domains. Moreover, symptoms reported by patients did not significantly vary during treatment. Treatment of elderly patients with NSCLC presenting with an impaired PS represents a hard challenge for clinicians. While platinum-based combination chemotherapy actually represents the gold standard treatment of patients with advanced NSCLC presenting with good PS, the best treatment for elderly patients or those with low PS is still debated [13] and focused clinical trials are warranted [14] . PS can be considered as one of the main determinants of outcome in advanced NSCLC with a median survival of 4-6 months, low RRs and 1-year survival of 20% in patients with impaired PS [15, 16] . In such population treatment, intent is palliative and single-agent chemotherapy is supported by the main bulk of data [2, [16] [17] [18] . Moreover, alsoelderly patients generally received a monochemotherapy. As a consequence, when low PS and older age coexist, single-agent chemotherapy is the best reasonable treatment option. With respect to PS alone, CGA represents a fundamental tool to obtain additive important prognostic informations and to select, among low-PS and/or elderly patients, those with good functional status able to receive an active treatment. In our study, CGA by means of BADL and IADL scores and geriatric syndromes evaluation was carried out early at patient screening time and only patients overcoming minimal scores entered the study. Such a selection represented a fundamental step and the reason for this is twofold: (i) we avoided unuseful and potentially toxic treatments to really unfit patients and (ii) we obtained a more homogenous population and, consequently, our results could be transferred to similar patients in clinical practice. Our results enforce the role of CGA in elderly and/or low-PS lung cancer patients and we strongly encourage its routine use in baseline patient evaluation. Our encouraging results could not be observed in a general elderly low-PS population, but with an accurate pretreatment selection, we obtained satisfactory results in terms of both safety and activity. Even if study population is mixed in terms of treatment setting (23 of 43 did not receive previous treatment), our results are in line with those of second-line treatment in unselected population [19] [20] [21] [22] and to first-line vinorelbine in elderly patients [23] . Such a close selection obviously reduced the number of elderly low-PS patients enrolled but it allowed us to obtain interesting results.
Given the palliative intent of chemotherapy in such population, safety aspects of study treatment are of primary importance. As reported in Table 4 , study treatment was extremely well tolerated. On a total of 187 cycles administered, we only observed one episode of not-febrile grade 3 neutropenia spontaneously recovered with and acceptable rate of low-grade hematological toxic effects never interfering with drug administration and without any treatment-related death or hospitalization. Also the incidence of grade 1-2 nonhematological side-effects was quite low without any influence on patient dietary intake, daily life or nonstudy drug administration. Patients did not report any worsening of their QoL scores in the five domains explored by FACT-L v4 questionnaire. The oral formulation of vinorelbine we used at the dose of 60 mg/m 2 coupled with the above mentioned patient selection could explain such positive safety results. Oral formulation could be an attractive option for patients. In fact, with the assumption of an equal efficacy, patients expressed a preference for oral over i.v. chemotherapy [24, 25] . Moreover, the oral formulation could potentially lessen nearly half of the major patient concerns about chemotherapy [26, 27] . The quite low toxicity incidence, the not-worsening of QoL and the oral formulation bear to the high patient compliance with a final dose intensity of 99.6% of the planned dose.
Coupled with an excellent toxicity profile, we observed an interesting activity of oral vinorelbine with an ORR of 18.6% and a CB of 48.8%. Survival data were also encouraging taking into account entry criteria with a median TTP of 4.0 months and a median OS of 8.0 months. It is of interest to compare these results, obtained in selected elderly/low-PS patients, with some recent clinical experiences in advanced unselected NSCLC patients with impaired PS. Baka et al. [28] explored the role of [29] reported the results of a doublet treatment with gemcitabine plus pemetrexed in a population of advanced NSCLC with a relatively large subgroup of patients with a PS of two or more (29%). Also in this case, patients with a PS of two or more achieved unsatisfactory results and appeared poorly suited for the two-drug regimen. Exploratory unplanned subgroup analysis revealed that neither sex nor histology was a predictor of survival ( Table 3) . As expected, PS 2 did better than PS 3 patients in terms of OS and the same was for patients receiving oral vinorelbine as second-line treatment and for older patients. While these results are expected regarding PS, they seem surprising with respect to age and treatment line. As possible explanations for this phenomenon, we suppose that patients treated with oral vinorelbine in second-line setting could have a good baseline PS at first-line therapy start time; consequently, in relation to a better basal PS, they could have a longer predicted survival. With respect to age, we can only suppose a different biology of cancer.
Oral vinorelbine has been widely used in the treatment of NSCLC [30] with a known (and usually good) safety profile. Interestingly, presented results are about in-line previous experiences with single-agent oral vinorelbine in elderly NSCLC (Table 5 ) [31] [32] [33] [34] [35] . Taking into account some differences in dosage schedule and PS of study populations, we can observe a close analogy of survival data. At a glance, our results in low-PS patients are similar to those obtained in more fit patients but this is only an apparent discrepancy; once more, our close baseline selection by means of CGA identified a 'fit' low PS population similar to unselected general elderly population of reported studies.
Also in our special population of selected elderly NSCLC patients with impaired PS, oral vinorelbine provided satisfactory safety and activity results. Our results also stressed the fundamental role of baseline patient selection by means of CGA. Even in elderly and low-PS patients, the presence of a good functional status is mandatory when deciding to treat a patient. Selected low-PS patients could be safely treated with oral vinorelbine with encouraging treatment activity and survival data. disclosure Table 5 . Clinical experiences with single-agent oral vinorelbine in elderly patients with advanced non-small-cell lung cancer 
